529 related articles for article (PubMed ID: 26492012)
1. O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson's disease.
Marotta NP; Lin YH; Lewis YE; Ambroso MR; Zaro BW; Roth MT; Arnold DB; Langen R; Pratt MR
Nat Chem; 2015 Nov; 7(11):913-20. PubMed ID: 26492012
[TBL] [Abstract][Full Text] [Related]
2. O-GlcNAcylation of α-Synuclein at Serine 87 Reduces Aggregation without Affecting Membrane Binding.
Lewis YE; Galesic A; Levine PM; De Leon CA; Lamiri N; Brennan CK; Pratt MR
ACS Chem Biol; 2017 Apr; 12(4):1020-1027. PubMed ID: 28195695
[TBL] [Abstract][Full Text] [Related]
3. O-GlcNAc modification inhibits the calpain-mediated cleavage of α-synuclein.
Levine PM; De Leon CA; Galesic A; Balana A; Marotta NP; Lewis YE; Pratt MR
Bioorg Med Chem; 2017 Sep; 25(18):4977-4982. PubMed ID: 28487126
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease.
Levine PM; Galesic A; Balana AT; Mahul-Mellier AL; Navarro MX; De Leon CA; Lashuel HA; Pratt MR
Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1511-1519. PubMed ID: 30651314
[TBL] [Abstract][Full Text] [Related]
5. Investigating the Effects of O-GlcNAc Modifications in Parkinson's Disease Using Semisynthetic α-Synuclein.
Galesic A; Pratt MR
Methods Mol Biol; 2020; 2133():313-326. PubMed ID: 32144674
[TBL] [Abstract][Full Text] [Related]
6. O-GlcNAcylation of truncated NAC segment alters peptide-dependent effects on α-synuclein aggregation.
Ryan P; Xu MM; Davey AK; Kassiou M; Mellick GD; Rudrawar S
Bioorg Chem; 2020 Jan; 94():103389. PubMed ID: 31753312
[TBL] [Abstract][Full Text] [Related]
7. O-GlcNAc regulation of autophagy and α-synuclein homeostasis; implications for Parkinson's disease.
Wani WY; Ouyang X; Benavides GA; Redmann M; Cofield SS; Shacka JJ; Chatham JC; Darley-Usmar V; Zhang J
Mol Brain; 2017 Jul; 10(1):32. PubMed ID: 28724388
[TBL] [Abstract][Full Text] [Related]
8. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.
Permanne B; Sand A; Ousson S; Nény M; Hantson J; Schubert R; Wiessner C; Quattropani A; Beher D
ACS Chem Neurosci; 2022 Apr; 13(8):1296-1314. PubMed ID: 35357812
[TBL] [Abstract][Full Text] [Related]
9. The Sulfur-Linked Analogue of O-GlcNAc (S-GlcNAc) Is an Enzymatically Stable and Reasonable Structural Surrogate for O-GlcNAc at the Peptide and Protein Levels.
De Leon CA; Levine PM; Craven TW; Pratt MR
Biochemistry; 2017 Jul; 56(27):3507-3517. PubMed ID: 28627871
[TBL] [Abstract][Full Text] [Related]
10. Enzymatic O-GlcNAcylation of α-synuclein reduces aggregation and increases SDS-resistant soluble oligomers.
Zhang J; Lei H; Chen Y; Ma YT; Jiang F; Tan J; Zhang Y; Li JD
Neurosci Lett; 2017 Aug; 655():90-94. PubMed ID: 28673834
[TBL] [Abstract][Full Text] [Related]
11. O-GlcNAc forces an α-synuclein amyloid strain with notably diminished seeding and pathology.
Balana AT; Mahul-Mellier AL; Nguyen BA; Horvath M; Javed A; Hard ER; Jasiqi Y; Singh P; Afrin S; Pedretti R; Singh V; Lee VM; Luk KC; Saelices L; Lashuel HA; Pratt MR
Nat Chem Biol; 2024 May; 20(5):646-655. PubMed ID: 38347213
[TBL] [Abstract][Full Text] [Related]
12. O-GlcNAc modification prevents peptide-dependent acceleration of α-synuclein aggregation.
Marotta NP; Cherwien CA; Abeywardana T; Pratt MR
Chembiochem; 2012 Dec; 13(18):2665-70. PubMed ID: 23143740
[TBL] [Abstract][Full Text] [Related]
13. O-GlcNAcylation inhibits the oligomerization of alpha-synuclein by declining intermolecular hydrogen bonds through a steric effect.
Wu K; Li D; Xiu P; Ji B; Diao J
Phys Biol; 2020 Dec; 18(1):016002. PubMed ID: 32906104
[TBL] [Abstract][Full Text] [Related]
14. Top/Middle-Down Characterization of α-Synuclein Glycoforms.
Miller SA; Jeanne Dit Fouque K; Hard ER; Balana AT; Kaplan D; Voinov VG; Ridgeway ME; Park MA; Anderson GA; Pratt MR; Fernandez-Lima F
Anal Chem; 2023 Dec; 95(49):18039-18045. PubMed ID: 38047498
[TBL] [Abstract][Full Text] [Related]
15. O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.
Ryan P; Xu M; Davey AK; Danon JJ; Mellick GD; Kassiou M; Rudrawar S
ACS Chem Neurosci; 2019 May; 10(5):2209-2221. PubMed ID: 30985105
[TBL] [Abstract][Full Text] [Related]
16. FTY720 Nanoformulation Induces O-GlcNacylation of Synuclein to Alleviate Synucleinopathy.
Sardoiwala MN; Boddu M; Biswal L; Karmakar S; Choudhury SR
ACS Chem Neurosci; 2024 Jan; 15(1):71-77. PubMed ID: 38109795
[TBL] [Abstract][Full Text] [Related]
17. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.
Vekrellis K; Stefanis L
Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256
[TBL] [Abstract][Full Text] [Related]
18. The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson's Disease.
Galvagnion C
J Parkinsons Dis; 2017; 7(3):433-450. PubMed ID: 28671142
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.
Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P
Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic roles for altered O-GlcNAcylation in neurodegenerative disorders.
Balana AT; Pratt MR
Biochem J; 2021 Jul; 478(14):2733-2758. PubMed ID: 34297044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
